| NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | RECRUITING | PHASE2 | 2025-05-01 | 2027-08 | 2027-02 |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 | 2025-02-13 | 2027-04 | 2026-11 |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-03-06 | 2028-10 | 2028-05 |
| NCT05848011 | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-09-28 | 2027-09 | 2026-09 |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | COMPLETED | PHASE2 | 2023-06-13 | 2025-01-23 | 2024-07-04 |
| NCT05261191 | A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy | COMPLETED | PHASE1 | 2022-09-26 | 2024-05-29 | 2024-05-29 |
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | RECRUITING | PHASE1 | 2022-07-13 | 2027-05 | 2026-11 |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-04-19 | 2025-08 | 2025-06-24 |
| NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | TERMINATED | PHASE2 | 2021-03-17 | 2022-07-29 | 2022-07-29 |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | WITHDRAWN | PHASE2, PHASE3 | 2019-10 | 2022-10 | 2020-10 |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | COMPLETED | PHASE2, PHASE3 | 2019-09-30 | 2025-03-25 | 2024-01-15 |
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | COMPLETED | PHASE1 | 2018-12-12 | 2025-01-27 | 2024-08-29 |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2018-11-21 | 2023-03-18 | 2023-03-18 |
| NCT03570918 | MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy | COMPLETED | PHASE1 | 2018-09-25 | 2021-09-28 | 2021-09-28 |
| NCT03531632 | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer | COMPLETED | PHASE1, PHASE2 | 2018-06-04 | 2020-02-08 | 2020-02-08 |
| NCT03406949 | MGD009/MGA012 Combination in Relapsed/Refractory Cancer | COMPLETED | PHASE1 | 2018-02-27 | 2022-04-27 | 2022-04-27 |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | COMPLETED | PHASE1 | 2017-08-18 | 2023-02-08 | 2023-02-08 |
| NCT02982941 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | COMPLETED | PHASE1 | 2016-12 | 2019-05-22 | 2019-05-22 |
| NCT02689284 | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | COMPLETED | PHASE1, PHASE2 | 2016-01 | 2021-01 | 2021-01 |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | TERMINATED | PHASE1 | 2015-09 | 2019-11-25 | 2019-11-25 |
| NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | COMPLETED | PHASE3 | 2015-08-24 | 2022-06-14 | 2021-08-11 |
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | COMPLETED | PHASE1 | 2015-07 | 2021-08-18 | 2021-08-18 |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | COMPLETED | PHASE1 | 2015-03-26 | 2018-09-26 | 2017-11-09 |
| NCT02376036 | Phase 1 Study of MGD010 in Healthy Subjects | COMPLETED | PHASE1 | 2015-02 | 2017-02 | 2017-02 |
| NCT02248805 | Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma | COMPLETED | PHASE1 | 2014-10 | 2018-07-02 | 2018-07-02 |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) | TERMINATED | PHASE1, PHASE2 | 2014-06-09 | 2022-07-05 | 2022-07-05 |
| NCT01918930 | Tissue Procurement Substudy for Participants in Study CP-MGA271-01 | TERMINATED | PHASE1 | 2013-07 | 2016-10 | 2016-10 |
| NCT01828021 | Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer | COMPLETED | PHASE2 | 2013-03 | 2017-04-14 | 2016-12-07 |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | COMPLETED | PHASE1 | 2011-07 | 2019-04-18 | 2019-04-18 |
| NCT01189422 | Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes | TERMINATED | PHASE1 | 2010-08 | 2011-02 | 2011-02 |
| NCT01148849 | Safety Study of MGAH22 in HER2-positive Carcinomas | COMPLETED | PHASE1 | 2010-07 | 2022-06-14 | 2022-06-14 |
| NCT00954915 | Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis | TERMINATED | PHASE1, PHASE2 | 2009-12 | 2010-07 | 2010-07 |
| NCT00920582 | Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus | TERMINATED | PHASE3 | 2009-09 | 2012-07 | 2012-04 |
| NCT00927953 | Treatment of West Nile Virus With MGAWN1 | TERMINATED | PHASE2 | 2009-05 | 2011-05 | 2011-02 |
| NCT00870818 | Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01) | TERMINATED | NA | 2009-02 | 2011-05 | 2011-02 |
| NCT00625586 | Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | TERMINATED | PHASE2 | 2008-04-15 | 2009-03-18 | 2009-01-21 |
| NCT00515385 | A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults | COMPLETED | PHASE1 | 2007-08 | 2009-01 | 2008-12 |
| NCT00385697 | The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus | COMPLETED | PHASE2, PHASE3 | 2006-10 | 2011-08 | 2010-06 |
| NCT00101972 | RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | COMPLETED | PHASE1 | 2004-12 | 2008-05 | 2008-05 |